Fundraising Fox

mbiomics

2 known investors

mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) based on gut microbiome consortia to treat severe and chronic diseases, with a pipeline spanning oncology (melanoma, NSCLC/renal cell carcinoma), IBD, and ASD. The company combines a data science platform, a proprietary strain library, co-culturing manufacturing, and screening analytics to design and produce indication-specific microbial therapeutics.

AI & Machine LearningBiotechHealthtech

Investors · 2

Bayern KapitalLandshut · $275K – $55M

Also in the syndicate · 1

MIG Fonds

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

mbiomics secures EUR 30 million for the further development of microbiome-based therapeutics - BioMbio-m.org · Apr 2026MIG Fonds and Bayern Kapital back mbiomics in €30M raise for its microbiome cancer co-therapy — TFNtechfundingnews.com · Apr 2026Munich’s mbiomics closes €30M to develop live bacterial productthenextweb.com · Apr 2026mbiomics GmbH Raises $35.3M | Signalbasetrysignalbase.com · Apr 2026mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeuticsglobenewswire.com · Apr 2026mbiomics Raises €13M in Series A Fundingfinsmes.com · Mar 2023

Frequently asked questions

What does mbiomics do?
mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) based on gut microbiome consortia to treat severe and chronic diseases, with a pipeline spanning oncology (melanoma, NSCLC/renal cell carcinoma), IBD, and ASD. The company combines a data science platform, a proprietary strain library, co-culturing manufacturing, and screening analytics to design and produce indication-specific microbial therapeutics.
Who are mbiomics's investors?
mbiomics's investors include Bayern Kapital.